Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Israel’s Taro Cancels Acquisition Pact With India’s Sun Pharma

This article was originally published in PharmAsia News

Executive Summary

Israel's Taro Pharmaceuticals has canceled its year-old agreement with India's Sun Pharmaceutical Industries to agree to a Sun subsidiary's takeover of the firm. Sun and Taro agreed last year to a $455 million acquisition by Aditya Acquisition, a Sun subsidiary, but Taro directors have voted unanimously to cancel the agreement after Taro managed to turn around its fortunes in the ensuing months. Sun, which owns just over a third of Taro, had offered to raise the original share offer, but Taro directors turned it down and exercised an agreement provision that allowed the Israeli drug maker to cancel the merger
Advertisement

Related Content

India’s Sun Pharma To Pursue Taro Merger As Q4 Profits Surge On U.S. Protonix Sales
Advertisement
UsernamePublicRestriction

Register

SC068589

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel